Retinol-binding protein 4: A possible role in cardiovascular complications

British Journal of Pharmacology

Volumn 164, Issue 8, 2011, Pages 1939-1948

  Mohapatra, Jogeswar ^a   Sharma, Manoranjan ^a   Acharya, Aviseka ^a   Pandya, Gaurav ^a   Chatterjee, Abhijit ^a   Balaraman, R ^b   Jain, Mukul R ^a  

^a ZYDUS RESEARCH CENTRE   (India)

^b M S UNIVERSITY OF BARODA   (India)

Author keywords

endothelial function; inflammation; LDL cholesterol; RBP4; rimonabant

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CYTOKINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYSORBATE 80; RETINOL BINDING PROTEIN 4; RIMONABANT; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL FUNCTION; C57BL 6 MOUSE; CARDIOVASCULAR DISEASE; CHOLESTEROL DIET; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE EXPRESSION; HYPERLIPIDEMIA; INFLAMMATION; LIPID DIET; MOUSE; MOUSE STRAIN; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE;

3T3-L1 CELLS; ADIPOKINES; ANIMALS; APOLIPOPROTEIN E3; ATHEROSCLEROSIS; BASE SEQUENCE; CARDIOVASCULAR DISEASES; CHOLESTEROL; DNA PRIMERS; FEMALE; GENE EXPRESSION REGULATION; HYPERCHOLESTEROLEMIA; INFLAMMATION; MICE; MICE, INBRED C57BL; OBESITY; PIPERIDINES; PYRAZOLES; REAL-TIME POLYMERASE CHAIN REACTION; RETINOL-BINDING PROTEINS, PLASMA;

EID: 81855187013     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01492.x     Document Type: Article

References (39)

1. Alexander SPH, Mathie A, Peters JA, (2008). Guide to receptors and channels (GRAC), 3rd edition (2008 revision). Br J Pharmacol 153 (Suppl. 2): S1-S209.
2. Balagopal P, Graham TE, Kahn BB, Altomare A, Funanage V, (2007). Reduction of elevated serum retinol binding protein (rbp4) in obese children by lifestyle intervention: association with sub-clinical inflammation. J Clin Endocrin Metab 92: 1971-1974. (Pubitemid 46997219)
3. Basualdo CG, Wein EE, Basu TK, (1997). Vitamin A (retinol) status of first nation adults with non-insulin-dependent diabetes mellitus. J Am Coll Nutr 16: 39-45. (Pubitemid 27073673)
4. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, et al,. (2003). The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63: 908-914. (Pubitemid 36368998)
5. Berg AH, Scherer PE, (2005). Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96: 939-949. (Pubitemid 40712793)
6. Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, et al,. (2006). Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 29: 2457-2461. (Pubitemid 44912252)
7. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, et al,. (2003). The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112: 423-431. (Pubitemid 38063771)
8. Croci T, Landi M, Galzin AM, Marini P, (2003). Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol 140: 115-122. (Pubitemid 37175837)
9. Dol-Gleizes F, Paumelle R, Visentin V, Marés A, Desitter P, Hennuyer N, et al,. (2009). Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 29: 12-18.
10. Dutta K, Nandi D, Bishayi B, (2009). Repeated systemic Escherichia coli infection enhances anti-oxidant response in hypercholesterolemic mice inducing cardiovascular inflammation. Inflammation 32: 89-98.
11. Eckel RH, (1997). Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 96: 3248-3250. (Pubitemid 27500134)
12. Erikstrup C, Mortensen OH, Pedersen BK, (2006). Retinol-binding protein 4 and insulin resistance. N Engl J Med 355: 1393-1394.
13. Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Trillou C, et al,. (2007). Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 46: 122-129. (Pubitemid 47171928)
14. Gary-Bobo M, Elachouri G, Scatton B, Le Fur G, Oury-Donat F, Bensaid M, (2006). The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 69: 471-478. (Pubitemid 43121944)
15. Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, et al,. (2006). Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 354: 2552-2563. (Pubitemid 43882351)
16. Han SH, Sakuma I, Shin EK, Koh KK, (2009). Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies. Prog Cardiovasc Dis 52: 126-140.
17. Ingelsson E, Lind L, (2009). Circulating retinol-binding protein 4 and subclinical cardiovascular disease in the elderly. Diabetes Care 32: 733-735.
18. Klöting N, Graham TE, Berndt J, Kralisch S, Kovacs P, Wason CJ, et al,. (2007). Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab 6: 79-87. (Pubitemid 46995778)
19. Kopelman PG, (2000). Obesity as a medical problem. Nature 404: 635-643. (Pubitemid 30205068)
20. Lau DCW, Bikramjit Dhillon B, Yan H, Szmitko PE, Verma S, (2005). Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol 288: H2031-H2041. (Pubitemid 40604084)
21. Lavie CJ, Millani RV, Ventura HO, (2009). Obesity and cardiovascular disease. risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 53: 1925-1932.
22. McGill HC Jr, McMahan CA, Herderick EE, Zieske AW, Malcom GT, Tracy RE, et al,. (2002). Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 105: 2712-2718. (Pubitemid 34615140)
23. Mohapatra J, Sharma M, Singh S, Pandya G, Chatterjee A, Balaraman R, et al,. (2009). Involvement of adipokines in rimonabant-mediated insulin sensitivity in ob/ob mice. J Pharm Pharmacol 61: 1493-1498.
24. Nissen SE, Nicholls SJ, Wolski K, Rodés-Cabau J, Cannon CP, Deanfield JE, et al,. (2008). Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 299: 1547-1560. (Pubitemid 351482794)
25. Niu J, Kolattukudy PE, (2009). Role of MCP-1 in cardiovascular disease: molecular mechanism and clinical implications. Clin Sci (Lond) 117: 95-109.
26. Park SE, Kim DH, Lee JH, Park JS, Kang ES, Ahn CW, et al,. (2009). Retinol-binding protein-4 is associated with endothelial dysfunction in adults with newly diagnosed type 2 diabetes mellitus. Atherosclerosis 204: 23-25.
27. Poirier B, Bidouard JP, Cadrouvele C, Marniquet X, Staels B, O'Connor SE, et al,. (2005). The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 7: 65-72.
28. Quadro L, Hamberger L, Colantuoni V, Gottesman ME, Blaner WS, (2003). Understanding the physiological role of retinol-binding protein in vitamin A metabolism using transgenic and knockout mouse models. Mol Aspects Med 24: 421-430. (Pubitemid 37324654)
29. Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman D, Colditz GA, et al,. (1995). Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol 141: 1117-1127.
30. Schäfer A, Pfrang J, Neumüller J, Fiedler S, Ertl G, Bauersachs J, (2008). The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats. Br J Pharmacol 154: 1047-1054. (Pubitemid 351915060)
31. Solini A, Santini E, Madec S, Rossi C, Muscelli E, (2009). Retinol-binding protein-4 in women with untreated essential hypertension. Am J Hypertens 22: 948-949.
32. Stokes KY, Dugas TR, Tang Y, Garg H, Guidry E, Bryan NS, (2009). Dietary nitrite prevents hypercholesterolemic microvascular inflammation and reverses endothelial dysfunction. Am J Physiol Heart Circ Physiol 296: H1281-H1288.
33. Takashima N, Tomoike H, Iwai N, (2006). Retinol-Binding Protein 4 and Insulin Resistance. N Engl J Med 355: 1392.
34. Tuomainen AM, Jauhiainen M, Kovanen PT, Metso J, Paju S, Pussinen PJ, (2008). Aggregatibacter actinomycetemcomitans induces MMP-9 expression and proatherogenic lipoprotein profile in apoE-deficient mice. Microb Pathog 44: 111-117. (Pubitemid 350297673)
35. Usui S, Ichimura M, Ikeda S, Okamoto M, (2009). Association between serum retinol-binding protein 4 and small dense low-density lipoprotein cholesterol levels in young adult women. Clin Chim Acta 399: 45-48.
36. Yan ZC, Liu DY, Zhang LL, Shen CY, Ma QL, Cao TB, et al,. (2007). Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferatoractivated receptor-d. Biochem Biophys Res Commun 354: 427-433. (Pubitemid 46172454)
37. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al,. (2005). Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436: 356-362. (Pubitemid 41065039)
38. Yao-Borengasser A, Varma V, Bodles AM, Rasouli N, Phanavanh B, Lee M, et al,. (2007). Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone. J Clin Endocrinol Metab 92: 2590-2597. (Pubitemid 47037362)
39. Zhang Q, Chang Z, Yang J, Wang Q, (2008). Antiatherogenic property of triterpenoids-enriched extract from the aerial parts of Salvia miltiorrhiza. Phytother Res 22: 1040-1045.